港股异动 | 荃信生物-B(02509)午后涨超10% 治疗PN注射液研究结果显示主要终点达标

智通财经06-18

智通财经APP获悉，荃信生物-B(02509)午后放量拉升逾10%，截至发稿，涨4.25%，报24.55港元，成交额213.89万港元。消息面上，荃信生物公布，QX005N注射液治疗结节性痒疹(PN)的II期临床试验数据在中华医学会第二十九次皮肤性病学术年会上以口头报告形式发布。基于试验数据，QX005N于今年1月31日被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。据悉，该试验为国内首个...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2444387176?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-06-18 14:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2444387176","market":"hk","top_or_hot":-1,"title":"港股异动 | 荃信生物-B(02509)午后涨超10% 治疗PN注射液研究结果显示主要终点达标","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，荃信生物-B(02509)午后放量拉升逾10%，截至发稿，涨4.25%，报24.55港元，成交额213.89万港元。消息面上，荃信生物公布，QX005N注射液治疗结节性痒疹(PN)的II期临床试验数据在中华医学会第二十九次皮肤性病学术年会上以口头报告形式发布。基于试验数据，QX005N于今年1月31日被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。据悉，该试验为国内首个...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1136655.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 荃信生物-B(02509)午后涨超10% 治疗PN注射液研究结果显示主要终点达标</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 荃信生物-B(02509)午后涨超10% 治疗PN注射液研究结果显示主要终点达标\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-18 14:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1136655.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，荃信生物-B(02509)午后放量拉升逾10%，截至发稿，涨4.25%，报24.55港元，成交额213.89万港元。消息面上，荃信生物公布，QX005N注射液治疗结节性痒疹(PN)的II期临床试验数据在中华医学会第二十九次皮肤性病学术年会上以口头报告形式发布。基于试验数据，QX005N于今年1月31日被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。据悉，该试验为国内首个...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1136655.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HSCEI","symbol_name":"国企指数","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1136655.html","article_id":"2444387176","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2444387176","pubTimestamp":1718690640,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，荃信生物-B(02509)午后放量拉升逾10%，截至发稿，涨4.25%，报24.55港元，成交额213.89万港元。消息面上，荃信生物公布，QX005N注射液治疗结节性痒疹(PN)的II期临床试验数据在中华医学会第二十九次皮肤性病学术年会上以口头报告形式发布。基于试验数据，QX005N于今年1月31日被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。据悉，该试验为国内首个由内地企业开展针对PN适应症的生物药临床试验，研究结果显示，本次临床试验各剂量组的主要终点完全达标。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HSCEI":"国企指数","07226":"XL二南方恒科","HSTECH":"恒生科技指数","02509":"荃信生物-B","BK1161":"生物科技","YANG":"三倍做空富时中国ETF-Direxion"},"translate_title":"Hong Kong stocks changed Quanxin Bio-B (02509) rose more than 10% in the afternoon for the treatment of PN injection. The results of the study showed that the primary endpoint met the standard","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02509":1,"07226":1,"HSCEI":1,"HSTECH":1,"YANG":1},"content_text":"智通财经APP获悉，荃信生物-B(02509)午后放量拉升逾10%，截至发稿，涨4.25%，报24.55港元，成交额213.89万港元。消息面上，荃信生物公布，QX005N注射液治疗结节性痒疹(PN)的II期临床试验数据在中华医学会第二十九次皮肤性病学术年会上以口头报告形式发布。基于试验数据，QX005N于今年1月31日被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。据悉，该试验为国内首个由内地企业开展针对PN适应症的生物药临床试验，研究结果显示，本次临床试验各剂量组的主要终点完全达标。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2444387176"}